Methods and compositions for treatment of attention deficit disorder
View Patent ↗Therapeutic compositions and methods for treatment of attention deficit disorder (ADD) or attention deficit hyperactivity disorder (ADHD) include dosage forms that deliver a therapeutic amount of active drug in a delayed and controlled release formulation. The dosage form can be administered at night and drug release is delayed for from 3 to 8 hours, followed by an ascending release rate.
1. A method of treating a condition in a subject with a disorder or condition responsive to the administration of a central nervous system stimulant, comprising orally administering an effective amount of an amphetamine, an amphetamine salt, an amphetamine prodrug, or a combination thereof to the subject, wherein the amphetamine, amphetamine salt, amphetamine prodrug, or combination thereof is administered orally in a single delayed release dosage comprising a core comprising a therapeutic amount of a central nervous system stimulant and at least one pharmaceutically acceptable excipient; a sustained release layer coating the core; and a delayed release layer coating the sustained release layer, which exhibits (i) a lag period of at least 5 hours during which the plasma concentration of amphetamine, an amphetamine salt, an amphetamine prodrug, or a combination thereof is less than 10% of the maximum concentration (C max ); (ii) a plasma area under the curve at 10 hours (AUC 0-10 ) after administration of less than about 7% of AUC 0-48 ; and (iii) wherein the time to C max (T max ) is between 12 and 19 hours after administration.
2. The method of claim 1 , wherein the effective amount is administered once a day.
3. The method of claim 1 wherein the amphetamine is amphetamine, a pharmaceutical amphetamine salt, dextroamphetamine or a pharmaceutical salt thereof, or lisdexamfetamine dimesylate, or a pharmaceutical salt thereof.
4. The method of claim 1 wherein Cmax occurs at greater than 15 hours after the administration.
5. The method of claim 1 , wherein the disorder or condition is attention deficit disorder, attention deficit hyperactivity disorder, excessive daytime sleepiness, major depressive disorder, bipolar depression, negative symptoms in schizophrenia, chronic fatigue, fatigue associated with chemotherapy or binge eating disorder.
6. A method of treating a condition in a subject with a disorder or condition responsive to the administration of a central nervous system stimulant, comprising orally administering an effective amount of a solid, oral pharmaceutical composition comprising:
a core comprising a therapeutic amount of a central nervous system stimulant and at least one pharmaceutically acceptable excipient;
a sustained release layer coating the core; and
a delayed release layer coating the sustained release layer,
and further wherein when the composition is administered to a human, i) no more than about 10% of the C max of central nervous system stimulant is detectable in the plasma 5 hours after administration, ii) plasma area under the curve at 10 hours (AUC0.10) after administration is less than about 7% of AUC0-48, and (iii) wherein the time to C max (T max ) is between 12 and 19 hours after administration.
7. The method of claim 6 , wherein the disorder or condition is attention deficit disorder, attention deficit hyperactivity disorder, excessive daytime sleepiness, major depressive disorder, bipolar depression, negative symptoms in schizophrenia, chronic fatigue, fatigue associated with chemotherapy or binge eating disorder.
8. The method of claim 6 , wherein the central nervous system stimulant is amphetamine, dextroamphetamine, or an isomer, racemic mixture, prodrug or pharmaceutical salt of any thereof.
9. The method of claim 6 , wherein the central nervous system stimulant is amphetamine or a pharmaceutical salt thereof.
10. The method of claim 6 , wherein the central nervous system stimulant is dextroamphetamine or a pharmaceutical salt thereof.
11. The method of claim 6 , wherein the central nervous system stimulant is lisdexamfetamine dimesylate or a pharmaceutical salt thereof.
12. The method of claim 6 , wherein the effective amount is from 5 mg-54 mg.
13. The method of claim 1 , wherein the disorder or condition is attention deficit disorder or attention deficit hyperactivity disorder.
14. The method of claim 13 , wherein the effective amount is from 5 mg-54 mg.